[Federal Register Volume 83, Number 245 (Friday, December 21, 2018)]
[Notices]
[Pages 65694-65695]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-27671]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: 
``Multifunctional RNA Nanoparticles and Methods of Uses'' and ``RNA/DNA 
Hybrid Nanoparticles Modified With Single Stranded RNA Toeholds and 
Uses Thereof''

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patent Applications listed in the 
Supplementary Information section of this notice to Sixfold Biosciences 
Inc., (``Sixfold'') of Walnut, California.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before January 7, 2019 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Jasmine Yang, Sr. Licensing and Patenting 
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 
1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, 
MD 20850-9702 Telephone: (240)-276-5530; Facsimile: (240)-276-5504 
Email: <a href="/cdn-cgi/l/email-protection#3a505b495753545f14435b545d7a545352145d554c"><span class="__cf_email__" data-cfemail="503a31233d393e357e29313e37103e39387e373f26">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: 

Intellectual Property

A. Multifunctional RNA Nanoparticles and Methods of Uses

1. U.S. Provisional Patent Application (Application No. 61/878,758) 
filed September 17, 2013, HHS Reference No.: E-765-2013-0-US-01
2. PCT Application (Application No. PCT/US2014/056007) filed September 
17, 2014, HHS Reference No.: E-765-2013-0-US-02
3. European Patent Application (Application No. 14780963.6) filed 
September 17, 2014, HHS Reference No.: E-765-2013-0-EP-03
4. Australian Patent Application (Application No. 2014321443) filed 
September 17, 2014, HHS Reference No.: E-765-2013-0-AU-04
5. Canadian Patent Application (Application No. 2,924,509) filed 
September 17, 2014, HHS Reference No.: E-765-2013-0-CA-05
6. Japanese. Patent Application (Application No. 2016-543964) filed 
September 17, 2014, HHS Reference No.: E-765-2013-0-JP-05
7. US Patent Application (Application No. 15/022,530) filed March 16, 
2016, HHS Reference No.: E-765-2013-0-US-07

B. RNA/DNA Hybrid Nanoparticles Modified with Single Stranded RNA 
Toeholds and Uses Thereof

1. U.S. Provisional Patent Application (Application No. 62/294,848) 
filed February 12, 2016, HHS Reference No.: E-078-2016-0-US-01
2. PCT Application (Application No. PCT/US2017/017661) filed February 
13, 2017, HHS Reference No.: E-078-2016-0-US-02
3. US Patent Application (Application No. 16/076,878) filed August 9, 
2018, HHS Reference No.: E-078-2016-0-US-03
4. European Patent Application (Application No. 17706653.7) filed 
September 12, 2018, HHS Reference No.: E-078-2016-0-EP-04

    The patent rights in these inventions have been assigned and/or 
exclusively

[[Page 65695]]

licensed to the government of the United States of America.
    The prospective exclusive license territory may be where patent 
applications are filed and the field of use may be limited to 
``Multifunctional RNA nanoparticle functionalized by RNA toeholds as a 
drug delivery agent carrying gene therapeutic or gene-editing cargo 
and/or aptamers''. Additional licensable fields of use are available 
(e.g. functionalized with proteins or imaging agent).
    The technologies disclose RNA and RNA/DNA (``R/DNA'') nanoparticles 
in the form of a hexameric ring that have arms attached off the sides 
of the ring in which the arms could be siRNAs, RNA aptamers, 
fluorescent dyes, imaging agents and/or proteins in various 
combinations and use of single-stranded RNA toeholds of lengths of 12 
nucleotides or less contained in nucleic acid-based nanoparticles, such 
as the nanoring, which trigger the association of these nanoparticles 
and activates multiple functionalities such as gene silencing and/or 
cell-specific targeting. This notice is made in accordance with 35 
U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will 
be royalty bearing, and the prospective exclusive license may be 
granted unless within fifteen (15) days from the date of this published 
notice, the National Cancer Institute receives written evidence and 
argument that establishes that the grant of the license would not be 
consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated; December 11, 2018.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2018-27671 Filed 12-20-18; 8:45 am]
 BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>